

MDHHS – MCIR Release Notes

Version 2023 – MCIR OLTP 2023 9.4.2.0 – RFC 215427

Release Date: March 29, 2023

Updates

- An issue has been corrected with missing Signature and Dates lines on some landscape records. (Ref. #1521)
- An issue with active VFC Inventory displaying on the short-dated Vaccine Report has been resolved. (Ref. #1568)
- An issue has been resolved to properly display Lead Results correctly on landscape records. This was an intermittent issue. (Ref. #1717)
- An issue has been resolved so sites can select CDC QI Reports. The report was blank for some sites. (Ref. #1982)

Forecasting & Assessment

- The PFR (Pfizer) Bivalent booster is now forecasted for 2 months after 3 dose PFR mono primary series. (Ref. #2166)
People ages 6 months and older are recommended to receive 1 bivalent mRNA booster dose after completion of any FDA-approved or FDA-authorized primary series or previously received monovalent booster dose(s) with the following exception: **children ages 6 months–4 years who receive 2 primary series doses of a monovalent Pfizer-BioNTech vaccine and 1 bivalent Pfizer-BioNTech vaccine for the third primary series dose are not authorized to receive a booster dose at this time.**

	10/01/2022	11/01/2022	01/22/2023	
SARS-CoV-2	COVID-19 PFR- BNT	COVID-19 PFR- BNT	COVID-19 PFR- BNT	Eligible Next Due 03/22/2023
	3mcg/0.2mL	3mcg/0.2mL	3mcg/0.2mL	
	4yrs 9mos	4yrs 10mos	5yrs	

- Forecast for CVX 228 has been updated second dose to 4 weeks. This also properly displays the correct name on official Immunization Record. (Ref. #2188)
- There are a couple smallpox-mpox vaccine updates. (Ref. #2233)
 - Accept and evaluate doses of smallpox-mpox vaccine given at ages less than 18 years.
 - MCIR had set licensure date of smallpox-mpox vaccine (JYNNEOS) of 9/24/19 when released during recent outbreak. The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) in August 2022 to also allow for use of JYNNEOS vaccine:
 - By subcutaneous injection for prevention of mpox disease in individuals younger than 18 years of age.
 - By intradermal injection for prevention of mpox disease in individuals 18 years of age and older.

- Two doses of JYNNEOS vaccine are recommended with either dosing regimen. The recommended dosing interval between the first and second dose of JYNNEOS vaccine for both the standard (subcutaneous administration) and the alternative (intra-dermal administration) dosing regimens is the same, 4 weeks (28 days +/- 3 days).
- Prior to administration in people younger than 18 years of age, clinicians should first contact their jurisdictional health department to facilitate consultation with CDC.
- Please see the following CDC link for additional information.
<https://www.cdc.gov/poxvirus/mpox/files/interim-considerations/mpox-jynneos-standing-orders-stand.pdf>
- MCIR will accept dose 1 of smallpox-mpox vaccine and forecast for dose 2 in 4 weeks for infants and children under 18 years of age.

Case example showing Orthopox - Series Complete
(30265880695)

Orthopox	09/07/2022 Smallpox mpox vaccine 17yrs 10mos	10/18/2022 Smallpox mpox vaccine 18yrs	Series Complete
-----------------	--	--	-----------------

- Forecast for Moderna 25 mcg was forecasting for 3 weeks to dose 2, instead of 4 weeks. The official Immunization Record was displaying Moderna Bivalent 25 mcg PED instead of Moderna 25 mcg. These issues have also been corrected. (Ref. #2188)

(17423126150)

SARS-CoV-2	01/05/2023 COVID-19 MOD 25 mcg ped 6mos 7dys	Moderna 25MCG PED DUE NOW
-------------------	---	---------------------------------

Status:

Moderna 25MCG PED	YES	2	02/02/2023	02/02/2023	03/02/2023
--------------------------	-----	---	------------	------------	------------

Official Immunization Record

Moderna 25MCG PED	2	02/02/2023	02/02/2023	03/02/2023
-------------------	---	------------	------------	------------

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at MDHHS-MCIRHelp@michigan.gov.